Heptares Partners with Cubist to Research New Medicines Targeting GPCRs

   Heptares Partners with Cubist to Research New Medicines Targeting GPCRs

  PR Newswire

  WELWYN GARDEN CITY, England and BOSTON, January 7, 2013

WELWYN GARDEN CITY, England and BOSTON, January 7, 2013 /PRNewswire/ --

Heptares Therapeutics, the leading GPCR drug discovery and development
company, today announced they have signed an agreement with Cubist
Pharmaceuticals, Inc. (Nasdaq: CBST) to collaborate on the research and
discovery of new medicines targeting G protein-coupled receptors (GPCRs),
which are membrane proteins involved in a broad range of biological processes
and diseases.

Under the terms of the agreement, Cubist will receive exclusive worldwide
rights to research, develop and commercialize products generated from the
collaboration. The collaborative research will focus on up to two GPCR drug
targets to be selected by Cubist. For the first target, Heptares will receive
$5.5 million (USD) upfront and up to approximately $4 million in research
funding plus milestones and royalties. Cubist also has the option to nominate
a second GPCR target at a later point in the collaboration, which Heptares has
agreed to work on according to pre-determined financials. Further terms of the
agreement are not disclosed.

Steve Gilman, Cubist Executive Vice President, Research & Development and
Chief Scientific Officer said: "We are pleased to collaborate with Heptares, a
recognized leader in the GPCR field, to pursue potential new GPCR drug
candidates. This partnership underscores our commitment to develop a robust
pipeline of novel products that address high unmet medical needs in patients
with acute diseases."

"We are very excited to work with Cubist, one of the fastest growing
biopharmaceutical companies in the world and a commercial leader in the acute
care therapeutics area," said Malcolm Weir, CEO of Heptares. "This agreement
further demonstrates the strength of our strategy to extend the reach of our
unique platform across the GPCR universe through partnerships with leading
pharmaceutical and specialty companies, while advancing our own proprietary
pipeline into clinical development."

About G protein-coupled receptors (GPCRs)

The GPCR superfamily is the largest and single most important family of drug
targets in the human body. It plays a central role in many biological
processes and is linked to a wide range of disease areas. GPCRs are expressed
in every type of cell in the body where their function is to transmit signals
from outside the cell across the membrane to signaling pathways within the
cell, between cells and between organ systems. There are over 375 GPCRs
encoded in the human genome, of which 225 have known ligands and 150 are
orphan targets. GPCRs are the site of action of 25-30% of current drugs. Six
of the top ten and 60 of the top 200 best-selling drugs in the US in 2010
target GPCRs.

About Heptares Therapeutics

Heptares creates new medicines targeting clinically important, yet
historically challenging, GPCRs (G protein-coupled receptors), a superfamily
of drug receptors linked to a wide range of human diseases. Leveraging our
advanced structure-based drug design technology platform, we have built an
exciting discovery and development pipeline of novel drug candidates, which
have the potential to transform the treatment of serious diseases, including
Alzheimer's disease, Parkinson's disease, schizophrenia, migraine and
diabetes. Our pharmaceutical partners include Shire, AstraZeneca, MedImmune,
Takeda and Cubist, and we are backed by MVM Life Science Partners, Clarus
Ventures, Novartis Venture Fund and Takeda Ventures. To learn more about
Heptares, please visit http://www.heptares.com .

Contact: Contact Information: Citigate Dewe Rogerson (for Heptares): Mark
Swallow, Chris Gardner, +44-(0)20-7282-2948, mark.swallow@citigatedr.co.uk.
Heptares Therapeutics Ltd: Malcolm Weir, Chief Executive Officer (UK),
+44-(0)1707-358-629, malcolm.weir@heptares.com; Dan Grau, President (USA),
+1-857-222-4586, dan.grau@heptares.com.
Press spacebar to pause and continue. Press esc to stop.